NEW YORK (GenomeWeb) – GenomeDx announced today that its prostate cancer classifier tests have been approved by the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program (CLEP).

The approval covers GenomeDx's Decipher Biopsy and Decipher Post-Op tests, which use genomic data to improve clinical decision-making following biopsy or radical prostatectomy, respectively, in men with prostate cancer.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Mar
08
Sponsored by
Swift Biosciences

This webinar will discuss an optimized protocol for methyl-CpG binding domain sequencing (MBD-seq), which enables comprehensive, adequately powered, and cost-effective large-scale methylome-wide association studies (MWAS) of almost all 28 million CpG sites in the genome.

Mar
13

This webinar will share how clinical genetics labs can integrate cytogenetics and molecular data to assess abnormalities using a single sample on a single workflow platform.

Apr
03

Proximity ligation technology generates multi-dimensional next-generation sequencing data that is proving to solve unmet needs in genomic research.